Please login to the form below

Not currently logged in

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects


Japanese pharma firm Eisai has launched an online portal to provide resources to help women with metastatic breast cancer.

The website,, includes information on the disease, treatment options, an overview of common side effects and management techniques, healthy lifestyle tips and strategies to manage finances throughout metastatic breast cancer treatment

Christine Verini, VP of corporate communications and advocacy at Eisai, said: “We are committed to supporting women by providing valuable information and educational resources that address the real-world challenges specific to living with metastatic breast cancer."

According to the company 69% of women perceive access to information as an essential part of their pathway, while 73% seek information about metastatic breast cancer and treatment options on a daily or weekly basis. Peer support is welcome too, with 69% finding it helpful to listen to or read about other people's experiences with breast cancer.

Verini commented: “These statistics suggest the need for centralised online resources to help women with MBC better cope with their disease.

“The launch of is an important step in providing MBC patients with a better understanding of their disease and their options, as well as guiding them to communities where they can find support by sharing experiences with other patients.”

Eisai is also sponsoring the 'Hear My Voice' campaign from Living Beyond Breast Cancer (LBBC), an effort to raise awareness for metastatic breast cancer and patients' experiences through the voices of women and men who have lived through the disease.

Eisai has shown a dedicated interest in breast cancer research, with its product Halaven (eribulin) being approved in countries including in Germany, Russia and the US. The drug, however, was not recommended by NICE in the UK due to possible side effects and - despite the company offering a patient access scheme - its cost.

Article by
Kirstie Pickering

16th October 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...